### 2.2.1 In vitro / physico-chemical data

A literature search was performed to collect available information on physicochemical properties of digoxin. The obtained information from the literature is summarized in the table below, and is used for model building.

| **Parameter**   | **Unit**    | **Digoxin literature** | **Description**                                  |
| :-------------- | ----------- | ----------------------------------- | ------------------------------------------------ |
| MW              | g/mol       | 780.93 ([Drugbank](#References)) | Molecular weight                                 |
| pKa             |             | none | Acid dissociation constant                   |
| Solubility (pH) | mg/L       | 64.8 (7) ([Drugbank](#References)) | Solubility                                       |
| logP            |             | 1.22, 1.62, 1.67  ([Alsenz 2007, Hinderling 1984, Atkinson 1988](#References)) | Partition coefficient between octanol and water  |
| fu              |             | 70.0, 71.0, 77.7 ([Hinderling 1984, Obach 2008, Neuhoff 2013](#References)) | Fraction unbound                                 |
| ATP1A2 KD | µmol/L | 0.0256 ([Katz 2010](#References)) | Dissociation constant |
| ATP1A2 koff | 1/min | n.a. | Dissociation rate constant |
| P-gp KM | µmol/L | 73.0, 177.0 ([Collett 2004, Troutman 2003](#References)) | Michaelis-Menten constant |
| P-gp kcat       | 1/min    | n.a. | P-gp catalytic rate constant |
| CLhep       | mL/min | n.a. | Hepatic plasma clearance |
| GFR fraction       | 1/min    | 1 | Fraction of filtered drug reaching the urine |
| Formulation       |     | solution | Formulation used in predictions |
| Cell permeabilities       |     | PK-Sim | Permeation across cell membranes |
| Partition coefficients       |     | Rodgers & Rowland | Organ-plasma partition coefficients |
| Specific intest. perm.       | dm/min   | n.a. | Normalized to surface area |
| Specific organ perm.       | dm/min   | n.a. | Normalized to surface area |


* ATP1A2: ATPase Na+/K+ transporting subunit alpha 2, CL: clearance, GFR: glomerular filtration rate, intest.: intestinal, n.a.: not available, perm.: permeability, P-gp: Pglycoprotein, PK-Sim: PK-Sim Standard calculation method, R + R: Rodgers and Rowland calculation method

  

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on digoxin in adults. 

The following publications were found in adults for model building and evaluation:

| Publication                         | Study  description                                           |
| ----------------------------------- | ------------------------------------------------------------ |
| [Becquemont   2001](#References)    | Becquemont, L. et al. Effect  of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol.  Ther. 70, 311–6 (2001). |
| [Ding   2004](#References)          | Ding, R. et al. Substantial  pharmacokinetic interaction between digoxin and ritonavir in healthy  volunteers. Clin. Pharmacol. Ther. 76, 73–84 (2004). |
| [Eckermann   2012](#References)     | Eckermann, G., Lahu, G.,  Nassr, N. & Bethke, T.D. Absence of pharmacokinetic interaction between  roflumilast and digoxin in healthy adults. J. Clin. Pharmacol. 52, 251–7  (2012). |
| [Friedrich   2011](#References)     | Friedrich, C. et al.  Evaluation of the pharmacokinetic interaction after multiple oral doses of  linagliptin and digoxin in healthy volunteers. Eur. J. Drug Metab.  Pharmacokinet. 36, 17–24 (2011). |
| [Greiner   1999](#References)       | Greiner, B. et al. The role of  intestinal P-glycoprotein in the interaction of digoxin and rifampin. J.  Clin. Invest. 104, 147–53 (1999). |
| [Gurley   2008](#References)        | Gurley, B.J., Swain, A.,  Williams, D.K., Barone, G. & Battu, S.K. Gauging the clinical  significance of P-glycoprotein-mediated herb-drug interactions: comparative  effects of St. John’s wort, Echinacea, clarithromycin, and rifampin on  digoxin pharmacokinetics. Mol. Nutr. food Res. 52, 772–9 (2008). |
| [Hayward   1978](#References)       | Hayward, R.P., Greenwood, H.  & Hamer, J. Comparison of digoxin and medigoxin in normal subjects. Br.  J. Clin. Pharmacol. 6, 81–6 (1978). |
| [Jalava   1997 ](#References)       | Jalava, K.M., Partanen, J.  & Neuvonen, P.J. Itraconazole decreases renal clearance of digoxin. Ther.  Drug Monit. 19, 609–13 (1997). |
| [Johne   1999](#References)         | Johne, A. et al.  Pharmacokinetic interaction of digoxin with an herbal extract from St John’s  wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66, 338–45 (1999). |
| [Kirby   2012](#References)         | Kirby B.J., Collier A.C., Kharasch E.D., Whittington D., Thummel K.E., Unadkat J.D. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos. 2012 Mar;40(3):610-6. |
| [Kirch   1986](#References)         | Kirch, W., Hutt, H.J.,  Dylewicz, P., Gräf, K.J. & Ohnhaus, E.E. Dose-dependence of the  nifedipine-digoxin interaction? Clin. Pharmacol. Ther. 39, 35–9 (1986). |
| [Koup   1975](#References)          | Koup, J.R., Greenblatt, D.J.,  Jusko, W.J., Smith, T.W. & Koch-Weser, J. Pharmacokinetics of digoxin in  normal subjects after intravenous bolus and infusion doses. J. Pharmacokinet.  Biopharm. 3, 181–92 (1975). |
| [Kramer   1979](#References)        | Kramer, W.G. et al.  Pharmacokinetics of digoxin: relationship between response intensity and  predicted compartmental drug levels in man. J. Pharmacokinet. Biopharm. 7,  47–61 (1979). |
| [Lalonde   1985](#References)       | Lalonde, R.L., Deshpande, R.,  Hamilton, P.P., McLean, W.M. & Greenway, D.C. Acceleration of digoxin  clearance by activated charcoal. Clin. Pharmacol. Ther. 37, 367–71 (1985). |
| [Larsen   2007](#References)        | Larsen, U.L. et al. Human  intestinal P-glycoprotein activity estimated by the model substrate digoxin.  Scand. J. Clin. Lab. Invest. 67, 123–34 (2007). |
| [Martin   1997](#References)        | Martin, D.E. et al. Lack of  effect of eprosartan on the single dose pharmacokinetics of orally  administered digoxin in healthy male volunteers. Br. J. Clin. Pharmacol. 43,  661–4 (1997). |
| [Ochs   1975](#References)          | Ochs, H., Bodem, G., Schäfer, P.K., Kodrat, G., Dengler, H.J. Absorption of digoxin from the distal parts of the intestine in man. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):95-7. |
| [Ochs   1978](#References)          | Ochs, H., Greenblatt, D.J.,  Bodem, G. & Harmatz, J.S. Dose-independent pharmacokinetics of digoxin in  humans. Am. Heart J. 96, 507–11 (1978). |
| [Oosterhuis   1991](#References)    | Oosterhuis, B., Jonkman, J.H.,  Andersson, T., Zuiderwijk, P.B. & Jedema, J.N. Minor effect of multiple  dose omeprazole on the pharmacokinetics of digoxin after a single oral dose.  Br. J. Clin. Pharmacol. 32, 569–72 (1991). |
| [Qiu   2010](#References)           | Qiu, R. et al. Lack of a  pharmacokinetic interaction between dimebon (latrepirdine) and digoxin in  healthy subjects. Am. Soc. Clin. Pharmacol. Ther. Meet. Atlanta, GA, USA  (2010). |
| [Ragueneau   1999](#References)     | Ragueneau, I. et al.  Pharmacokinetic and pharmacodynamic drug interactions between digoxin and  macrogol 4000, a laxative polymer, in healthy volunteers. Br. J. Clin.  Pharmacol. 48, 453–6 (1999). |
| [Rengelshausen   2003](#References) | Rengelshausen, J. et al.  Contribution of increased oral bioavailability and reduced nonglomerular  renal clearance of digoxin to the digoxin-clarithromycin interaction. Br. J.  Clin. Pharmacol. 56, 32–8 (2003). |
| [Rodin   1988](#References)         | Rodin, S.M., Johnson, B.F.,  Wilson, J., Ritchie, P. & Johnson, J. Comparative effects of verapamil  and isradipine on steady-state digoxin kinetics. Clin. Pharmacol. Ther. 43,  668–72 (1988). |
| [Steiness   1982](#References)      | Steiness, E., Waldorff, S.  & Hansen, P.B. Renal digoxin clearance: dependence on plasma digoxin and  diuresis. Eur. J. Clin. Pharmacol. 23, 151–4 (1982). |
| [Tayrouz   2003](#References)       | Tayrouz, Y. et al.  Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor  RH40. Clin. Pharmacol. Ther. 73, 397–405 (2003). |
| [Tsutsumi   2002](#References)      | Tsutsumi, K. et al. The effect  of erythromycin and clarithromycin on the pharmacokinetics of intravenous  digoxin in healthy volunteers. J. Clin. Pharmacol. 42, 1159–64 (2002). |
| [Vaidyanathan   2008](#References)  | Vaidyanathan, S. et al.  Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination  with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of  P-glycoprotein in the disposition of aliskiren. J. Clin. Pharmacol. 48, 1323–38  (2008). |
| [Verstuyft   2003](#References)     | Verstuyft, C. et al.  Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.  Clin. Pharmacol. Ther. 73, 51–60 (2003). |
| [Wagner   1981](#References)        | Wagner, J.G., Popat, K.D.,  Das, S.K., Sakmar, E. & Movahhed, H. Evidence of nonlinearity in digoxin  pharmacokinetics. J. Pharmacokinet. Biopharm. 9, 147–66 (1981). |
| [Westphal   2000](#References)      | Westphal, K. et al. Oral  bioavailability of digoxin is enhanced by talinolol: evidence for involvement  of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68, 6–12 (2000). |